NCT05653492Active, not recruitingPhase 2
Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease
Safety, Feasibility, and Tolerability of Sulforaphane in Children with CKD
Source: ClinicalTrials.gov · Last updated 19 Sept 2024
Brief summary (registry, in English)
This purpose of this study is to investigate potential new therapeutics in pediatric chronic kidney disease (CKD). The specific aims are to identify safe dosing and tolerability of sulforaphane (SFN) supplementation in children with moderate and advanced CKD. Secondary objectives will include preliminary exploration of changes in oxidative and inflammatory biomarkers in response to SFN supplementation in this population.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 7 Dec 2022
- Start date
- 15 May 2023
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- University of Rochester
- Diseases
- Chronic kidney disease
- NCT number
- NCT05653492
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 12
- From 15 May 2023 to the primary completion date, 30 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients will also be excluded if they are currently taking anticoagulants, immunosuppression, or chemotherapeutics
Other illness
- cancer or HIV diagnosis
- history of solid organ transplantation (including kidney transplant)
- structural heart disease
Other
- weight \<30 kg
- currently pregnant or plan to become pregnant
- life expectancy is less than one year
Who the study is looking for
- diagnosis of chronic of kidney disease
- have eGFR 20-59 mL/min/1.73m2 at the time of enrollment
- parents must be able to provide consent
Age in the registry: 1 year to 17 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Rochester Medical Center Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.